From a Diversified Conglomerate to a CDMO Rising Star: Lotte's Foray into Biopharmaceuticals Aims to Conquer the Global Market

As early as in 2014, the South Korean government is proactively develop prospect and development strategy of the biological pharmaceutical industry, to promote innovation and progress in the field of biological medicine and Biobetter similar, as South Korea in the key areas laid a solid foundation for the future development. This strategy, not only inspired Samsung life and self group of the sustainable development of famous enterprises, such as South Korea's Lotte group are attracted to the such big diversified into the vast blue ocean of biological medicine industry.

In July 2024, Lotte biological agents in Incheon, South Korea pine island biological park to start the construction of the new plant, marks its layout in the field of biological medicine took a substantive step. Lotte is expected to invest about 4.6 trillion won to build a biopomedicine production facility that meets international standards by 2030. The first phase of the new plant will establish a production capacity of 120,000 liters, covering the complete industrial chain from cell line development to finished product production. The move not only demonstrates Lotte's determination, but also heralds a new milestone for the Korean biomedical industry.

In addition, it has introduced the biological risk initiative plan, aims at providing a local biotech companies with hatching and growth platform, by sharing resources and knowledge, promote the formation of industrial cluster and prosperity. In this way, Lotte not only on the production side, more on the innovation of ecological construction has played a key role.

Prior to this, Rakyat Biologics has successfully entered the contract development and manufacturing (CDMO) business by acquiring Bristol-Myers Squibb's manufacturing facility in the United States. Subsequently, the company has further expanded new services such as antibody conjugate drugs (ADC), demonstrating strong business integration and innovation capabilities. Industry experts generally believe that with Lotte Group's strong financial support, diversified business background and deep understanding of the biomedical industry, Lotte Biologics is likely to become a "bright new star" leading the new trend of the industry.

South Korea's Lotte group active in the field of biomedical layout, not only embodies the discerning to the global market trend, also shows the south Korean firms on the innovation and the globalization strategy of determination and strength. With the development of a series of projects, and South Korea in the biological pharmaceutical industry will further enhance the international status, inject new vitality to the development of global health.